# US 10,869,847 B2 · Ceramide composition and method of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,847 B2
- Document ID: US10869847B2
- Status: Granted
- Kind: B2
- Application number: 16/046,246
- Filed: 2018-07-26
- Published: 2019-01-31
- Granted: 2020-12-22
- Earliest claimed: 2006-07-06
- Assignees: Case Western Reserve University; The Penn State Research Foundation
- Applicants: Case Western Reserve University; The Penn State Research Foundation
- Inventors: Eric Pearlman; Mark Kester
- Web page: https://patentgrep.com/patent/US10869847B2

## CPC

- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating and preventing diseases associated with neutrophil infiltration, particularly ocular diseases, is provided, which method comprises administering to a subject in need thereof an effective amount of ceramide or a derivative thereof. Also provided is a composition for treating diseases associated with neutrophil infiltration, the composition comprising ceramide or a derivative thereof.

## Claims

### Claim 1

A method for treating ocular tissue injury or diseases comprising administering to a subject in need thereof a composition comprising a C6-ceramide containing nanoliposome, wherein the ocular disease is a disease associated with neutrophil infiltration in a cell.

### Claim 2 (depends on 1)

The method of claim 1 wherein the ceramide thereof is administered at a dosage of about 1 nanogram to about 100 micrograms per day.

### Claim 3 (depends on 1)

The method of claim 1 wherein the composition inhibits mitogen-activated protein (MAP) kinases signaling.

### Claim 4 (depends on 3)

The method of claim 3 wherein the MAP kinases is at least one of JNK and p38.

### Claim 5 (depends on 1)

The method of claim 1 wherein the ceramide downregulates chemotatic mediators that recruit neutrophils to the site of tissue injury via Toll-like and cytokine receptors.

### Claim 6 (depends on 1)

The method of claim 1 wherein the ocular disease is a disease of the anterior eye.

### Claim 7 (depends on 6)

The method of claim 6 wherein the ocular disease is at least one of keratitis, endophthalmitis, uveitis, conjunctivitis, blepharitis, contact lens-induced peripheral ulcer and corneal dystrophy.

### Claim 8 (depends on 1)

The method of claim 1 wherein the ocular disease is a disease of the posterior eye.

### Claim 9 (depends on 8)

The method of claim 8 wherein the ocular disease is at least one of retinitis pigmentosa, diabetic retinopathy, macular degeneration and ocular toxoplasmosis.

### Claim 10 (depends on 1)

The method of claim 1 wherein the ocular disease is caused by refractive or laser surgery.

### Claim 11

A method for preventing ocular diseases associated with neutrophil infiltration in a cell comprising administering to a subject in need thereof a composition comprising a C6-ceramide containing nanoliposome.

### Claim 12 (depends on 11)

The method of claim 11 wherein the ocular disease is a disease of the anterior eye.

### Claim 13 (depends on 12)

The method of claim 12 wherein the ocular disease is at least one of keratitis, endophthalmitis, uveitis, conjunctivitis, blepharitis, contact lens-induced peripheral ulcer and corneal dystrophy.

### Claim 14 (depends on 11)

The method of claim 11 wherein the ocular disease is a disease of the posterior eye.

### Claim 15 (depends on 14)

The method of claim 14 wherein the ocular disease is at least one of retinitis pigmentosa, diabetic retinopathy, macular degeneration and ocular toxoplasmosis.